Accelr8's Q2 Revenues Drop Sharply As Novartis Deal Ends

genomeweb
360dx

Accelr8's Q2 Revenues Drop Sharply As Novartis Deal Ends

Mar 21, 2012

NEW YORK (GenomeWeb News) – Accelr8 reported last week that its fiscal second-quarter revenues plummeted to $8,328 from $313,568 a year ago as a result of the expiration of an agreement with Novartis.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

In Brief This Week: Baby Genes, J&J Innovation, Myriad Genetics, Merck, More
People in the News: Garret Lam, Kenneth Bloom, Joseph Caruso
Roche to Close NimbleGen Site, Lay Off 79 by Mid-2020
New Products Posted to GenomeWeb: Thermo Fisher Scientific, Twist Bioscience, 10X Genomics, More
LexaGene Announces C$5M Bought Deal Financing
Large Study Uncovers Genetic Connections Between Numerous Psychiatric Disorders

The Scan

Privacy Policy Information, Please

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

Moving the Parts About

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

This Week in Science

In Science this week: genetic overlap among many psychiatric disorders, and more.

Just Skip that Step

The Economist writes that an increasing number of scientific journals don't do peer review.

Main menu